Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papilloma Virus (HPV) Vaccine Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Participatory, Efficient
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Phase 2 Interventional

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

NCT07806617
View directory record Official record
Conditions
Warts, Verruca (Warts), Verruca Vulgaris
Interventions
9-valent human papillomavirus vaccine, Sterile Saline
Biological · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stories to Prevent (StoP) HPV Cancers

NCT06808776
View directory record Official record
Conditions
Human Papillomavirus Vaccination, Emotions
Interventions
Cancer survivor narrative, Healthy eating tips
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 8, 2026, 6:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy

NCT05860725
View directory record Official record
Conditions
Human Papillomavirus Infection, Vaccination Hesitancy
Interventions
PSA Development, HPV vaccination focused social marketing campaign
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

NCT03442062
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

NCT00828555
View directory record Official record
Conditions
Influenza Vaccine, Papillomavirus Infection, Pertussis
Interventions
Vaccination Program
Other
Lead sponsor
Duke University
Other
Eligibility
12 Years to 26 Years · Female only
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Burlington, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

NCT00231413
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Aurora, Colorado • Golden, Colorado • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

NCT00003977
View directory record Official record
Conditions
Cervical Cancer
Interventions
human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 8, 2026, 6:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi

NCT05658198
View directory record Official record
Conditions
Human Papillomavirus Vaccination
Interventions
Counseling
Behavioral
Lead sponsor
Plan A Health, Inc
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louise, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High and Low Resource Interventions to Promote HPV Vaccines

NCT03824093
View directory record Official record
Conditions
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions
AFIX Only, AFIX+ Provider Communication Training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents

NCT02236273
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Conventional text message reminder, Enhanced text message reminders
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy

NCT00727636
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Gardasil vaccine
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study

NCT01908517
View directory record Official record
Conditions
Patient Compliance
Interventions
HPV Vaccine Electronic Reminders
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
9 Years to 17 Years
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Greenville, North Carolina • Snow Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125
View directory record Official record
Conditions
Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions
Point-of-Care Prompt
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
7,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 8, 2026, 6:26 PM EDT
Recruiting Phase 2 Interventional

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

NCT07454915
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
Interventions
PVX4 Combination Product, Placebo Control
Combination Product · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Standing Orders Optimization

NCT05742386
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Communication training, Communication training enhanced with standing orders optimization
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

NCT03759236
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Health Messaging via SMS, CDC Health Pamphlets
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Not applicable Interventional

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

NCT02558803
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer, Genital Warts, Oropharyngeal Cancer
Interventions
Simple Reminder
Behavioral
Lead sponsor
Regenstrief Institute, Inc.
Other
Eligibility
11 Years to 17 Years
Enrollment
1,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 8, 2026, 6:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

NCT04247282
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Neoplasms
Interventions
M7824, N803, TriAd vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 8, 2026, 6:26 PM EDT